CA-TRICENTIS
15.1.2020 19:24:05 CET | Business Wire | Press release
Tricentis, the leader in continuous testing for DevOps, announced that it has acquired SpecFlow, the biggest and most trusted BDD solution for .NET developers around the world. SpecFlow’s pragmatic approach to specification-by-example has helped agile development teams improve collaboration with business stakeholders to build and deliver higher quality software.
SpecFlow will continue to remain a free, open source offering for the software development and testing communities. SpecFlow+ , SpecFlow’s commercial offering, and SpecMap , an Azure DevOps extension for user story mapping, will now be offered for free to meet the needs of scaling BDD across the enterprise – all backed by Tricentis’ leading innovation in continuous testing.
With this acquisition, Tricentis continues to extend its leadership in the open source and developer-led testing market. SpecFlow is Tricentis’ second acquisition in this market within the past year, with further acquisitions planned in the coming months. In 2019, Tricentis acquired TestProject , the world’s first free, cloud based test automation platform leveraging Selenium and Appium. The acquisition of SpecFlow adds best-in-class support for BDD and .NET developers to round out Tricentis’ comprehensive open source testing platform.
“BDD is becoming broadly relevant in enterprises for their digital transformation,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “As business requirements change at DevOps speed, teams need a way to document how their applications should behave across highly integrated systems. Without built-in test automation to this shared understanding, software delivery leads to production bugs and poor user experiences. SpecFlow’s ability to create this shared business understanding, connected with automated tests, makes it the most trusted BDD platform for .NET development.”
SpecFlow was developed by TechTalk as the open source port of Cucumber for .NET in 2009. Since then, SpecFlow has gathered a massive open source community, with more than 9.6 million downloads and a user base that continues to grow at more than 3,000 downloads per day.
SpecFlow provides a way to define, manage and automatically execute human-readable acceptance tests in .NET projects. By using human-readable syntax, known as Gherkin (“Given-When-Then”), SpecFlow helps software delivery teams to create a common business understanding of how their systems should behave. Its integration with popular developer tools like Selenium and Microsoft Visual Studio have made SpecFlow the BDD standard to bridge the communication gap between developers, testers and business users.
“I’m extremely proud of the community that SpecFlow has fostered over the years,” said Christian Hassa, Owner and Managing Partner at TechTalk. “TechTalk is happy to have found a partner in Tricentis who is committed to the BDD community and to significantly expand on our vision for SpecFlow while keeping it independent.”
About SpecFlow
SpecFlow is the world’s leading open-source Behavior-Driven Development framework for .NET. SpecFlow facilitates collaboration between teams in small and large enterprises, allows you to automate tests written in human-readable language, and helps stakeholders build up a shared understanding of software systems. Learn more about SpecFlow at https://specflow.org .
About TechTalk
TechTalk is a Central European company that specializes in agile methods, agile development, and agile coaching. TechTalk was a first mover in the agile community, realized the potential of Behavior-Driven Development at an early stage and started developing SpecFlow in 2008. TechTalk released SpecFlow as an open-source project in 2009 to involve the agile community and accelerate the growth and adoption of SpecFlow. Learn more about TechTalk at https://techtalk.at or follow us on LinkedIn , Twitter .
About Tricentis
With the industry’s #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases–transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.
Tricentis is the only vendor to achieve “Leader” status in all three top analyst reports (i.e., the “Triple Crown”). This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1600+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent–increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.
Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn , Twitter , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005741/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom